Research & Literature

Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.

Schmidt-Erfurth U, Waldstein SM, Deak GG, et al.

Ophthalmology 2015; (122(4)):822-32.

Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration.

Keane PA, de Salvo G, Sim DA, et al.

Clinical ophthalmology (Auckland, N.Z.) 2015; (9()):353-66 doi:10.2147/OPTH.S59012.

Recent developments in the management of dry age-related macular degeneration.

Buschini E, Fea AM, Lavia CA, et al.

Clinical ophthalmology (Auckland, N.Z.) 2015; (9()):563-74 doi:10.2147/OPTH.S59724.

Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.

Agarwal A, Rhoades WR, Hanout M, et al.

Clinical ophthalmology (Auckland, N.Z.) 2015; (9()):1001-15 doi:10.2147/OPTH.S74959.

Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature.

Stanescu-Segall D, Balta F, Jackson TL

Survey of ophthalmology 2016; (61(1)):18-32.

OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY VERSUS TRADITIONAL MULTIMODAL IMAGING IN ASSESSING THE ACTIVITY OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION: A New Diagnostic Challenge.

Coscas GJ, Lupidi M, Coscas F, et al.

Retina (Philadelphia, Pa.) 2015; (35(11)):2219-28 doi:10.1097/IAE.0000000000000766.

Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial.

Rakoczy EP, Lai CM, Magno AL, et al.

Lancet (London, England) 2015; (386(10011)):2395-403.

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.

García-Layana A, Figueroa MS, Araiz J, et al.

Drugs & aging 2015; (32(10)):797-807 doi:10.1007/s40266-015-0300-y.

Incidence and clinical features of post-injection endophthalmitis according to diagnosis.

Rayess N, Rahimy E, Shah CP, et al.

The British journal of ophthalmology 2016; (100(8)):1058-61 doi:10.1136/bjophthalmol-2015-307707.

Age-related macular degeneration: Complement in action.

van Lookeren Campagne M, Strauss EC, Yaspan BL

Immunobiology 2016; (221(6)):733-9.

Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.

Sharma S, Toth CA, Daniel E, et al.

Ophthalmology 2016; (123(4)):865-75.

Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration.

Rosenfeld PJ

Investigative ophthalmology & visual science 2016; (57(9)):OCT14-26 doi:10.1167/iovs.16-19969.

One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study.

Veritti D, Sarao V, Parravano M, et al.

European journal of ophthalmology 2017; (27(1)):74-79 doi:10.5301/ejo.5000880.

A review of optical coherence tomography angiography (OCTA).

de Carlo TE, Romano A, Waheed NK, Duker JS

International journal of retina and vitreous 2015; (1()):5 doi:10.1186/s40942-015-0005-8.

Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review.

Merani R, Hunyor AP

International journal of retina and vitreous 2015; (1()):9 doi:10.1186/s40942-015-0010-y.

OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY REVEALS BLOOD FLOW IN CHOROIDAL NEOVASCULAR MEMBRANE IN REMISSION PHASE OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Ichiyama Y, Sawada T, Ito Y, et al.

Retina (Philadelphia, Pa.) 2017; (37(4)):724-730 doi:10.1097/IAE.0000000000001576.

Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel.

Koh A, Lanzetta P, Lee WK, et al.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2017; (6(3)):296-302 doi:10.22608/APO.2016125.

Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.

Evans JR, Lawrenson JG

The Cochrane database of systematic reviews 2017; (7()):CD000254 doi:10.1002/14651858.CD000254.pub4.

Relationships of orientation discrimination threshold and visual acuity with macular lesions in age-related macular degeneration.

Fu H, Zhang B, Tong J, et al.

PloS one 2017; (12(9)):e0185070 doi:10.1371/journal.pone.0185070.

Challenges Associated with Estimating Utility in Wet Age-Related Macular Degeneration: A Novel Regression Analysis to Capture the Bilateral Nature of the Disease.

Hodgson R, Reason T, Trueman D, et al.

Advances in therapy 2017; (34(10)):2360-2370 doi:10.1007/s12325-017-0620-x.

PREVALENCE OF POLYPOIDAL CHOROIDAL VASCULOPATHY IN WHITE PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Systematic Review and Meta-Analysis.

Lorentzen TD, Subhi Y, Sørensen TL

Retina (Philadelphia, Pa.) 2018; (38(12)):2363-2371 doi:10.1097/IAE.0000000000001872.

EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB IN ASIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Subgroup Analyses From the VIEW Trials.

Wong TY, Cheung CMG, Lai TYY, et al.

Retina (Philadelphia, Pa.) 2019; (39(3)):537-547 doi:10.1097/IAE.0000000000001986.

Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.

Xu K, Chin EK, Bennett SR, et al.

Ophthalmology 2018; (125(8)):1279-1286 doi:10.1016/j.ophtha.2018.01.022.

Age-related macular degeneration.

Mitchell P, Liew G, Gopinath B, Wong TY

Lancet (London, England) 2018; (392(10153)):1147-1159 doi:10.1016/S0140-6736(18)31550-2.

Asian age-related macular degeneration: from basic science research perspective.

Yanagi Y, Foo VHX, Yoshida A

Eye (London, England) 2019; (33(1)):34-49 doi:10.1038/s41433-018-0225-x.

[Update from France Macula Federation: Diagnosis of wet AMD].

Wolff B, De Bats F, Tick S, et al.

Journal francais d'ophtalmologie 2018; (41(9)):857-861 doi:10.1016/j.jfo.2018.05.004.

The diagnostic accuracy of OCT angiography in naive and treated neovascular age-related macular degeneration: a review.

Perrott-Reynolds R, Cann R, Cronbach N, et al.

Eye (London, England) 2019; (33(2)):274-282 doi:10.1038/s41433-018-0229-6.

Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study.

Wykoff CC, Ou WC, Brown DM, et al.

Ophthalmology. Retina 2017; (1(4)):314-321 doi:10.1016/j.oret.2016.12.004.

Two-Year Risk of Exudation in Eyes with Nonexudative Age-Related Macular Degeneration and Subclinical Neovascularization Detected with Swept Source Optical Coherence Tomography Angiography.

Yang J, Zhang Q, Motulsky EH, et al.

American journal of ophthalmology 2019; (208()):1-11 doi:10.1016/j.ajo.2019.06.017.

Optical Coherence Tomography-Angiography of Different Choroidal Neovascularization Subtypes in Wet Age-related Macular Degeneration.

Stavrev VN, Sivkova NP, Koleva-Georgieva DN

Folia medica 2019; (61(2)):317-326.

Oxymetazoline: reduction of subconjunctival hemorrhage incidence after intravitreal injections.

Gonzalez-Saldivar G, Pita-Ortiz IY, Flores-Villalobos EO, et al.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2019; (54(4)):513-516 doi:10.1016/j.jcjo.2018.09.006.

Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy.

Kokame GT, deCarlo TE, Kaneko KN, et al.

Ophthalmology. Retina 2019; (3(9)):744-752 doi:10.1016/j.oret.2019.04.018.

TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS.

Starr MR, Kung FF, Mejia CA, et al.

Retina (Philadelphia, Pa.) 2020; (40(9)):1665-1672 doi:10.1097/IAE.0000000000002668.

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.

Spaide RF, Jaffe GJ, Sarraf D, et al.

Ophthalmology 2020; (127(5)):616-636 doi:10.1016/j.ophtha.2019.11.004.

Polypoidal choroidal vasculopathy in Canada.

Lam WC, Choudhry N, Wong D

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2020; (55(3)):199-211 doi:10.1016/j.jcjo.2019.10.011.

Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 40.

Christakis PG, Agrón E, Klein ML, et al.

Ophthalmology 2020; (127(6)):784-792 doi:10.1016/j.ophtha.2019.11.016.

Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial.

Ramakrishnan MS, Yu Y, VanderBeek BL

JAMA ophthalmology 2020; (138(3)):237-242 doi:10.1001/jamaophthalmol.2019.4577.

Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration.

Schmidt-Erfurth U, Vogl WD, Jampol LM, Bogunović H

Ophthalmology 2020; (127(9)):1211-1219 doi:10.1016/j.ophtha.2020.03.010.

Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and Treatment.

Chaikitmongkol V, Cheung CMG, Koizumi H, et al.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; (9(3)):260-268 doi:10.1097/01.APO.0000656992.00746.48.

Nonexudative Macular Neovascularization - A Systematic Review of Prevalence, Natural History, and Recent Insights from OCT Angiography.

Laiginhas R, Yang J, Rosenfeld PJ, Falcão M

Ophthalmology. Retina 2020; (4(7)):651-661 doi:10.1016/j.oret.2020.02.016.

Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration.

Cheong KX, Teo KYC, Cheung CMG

Survey of ophthalmology 2021; (66(1)):68-97 doi:10.1016/j.survophthal.2020.05.003.

Rhegmatogenous Retinal Detachment after Intravitreal Injection.

Brown KR, Yannuzzi NA, Smiddy WE, et al.

Ophthalmology. Retina 2021; (5(2)):178-183 doi:10.1016/j.oret.2020.07.007.

Emerging Therapies in Nonexudative Age-Related Macular Degeneration in 2020.

Samanta A, Aziz AA, Jhingan M, et al.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2021; (10(4)):408-416 doi:10.1097/APO.0000000000000355.

Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review.

Tan Y, Fukutomi A, Sun MT, et al.

Survey of ophthalmology 2021; (66(6)):926-932 doi:10.1016/j.survophthal.2021.03.001.

Clinical Update on Metamorphopsia: Epidemiology, Diagnosis and Imaging.

Hanumunthadu D, Lescrauwaet B, Jaffe M, et al.

Current eye research 2021; (46(12)):1777-1791 doi:10.1080/02713683.2021.1912779.

IMPACT OF RESIDUAL SUBRETINAL FLUID VOLUMES ON TREATMENT OUTCOMES IN A SUBRETINAL FLUID-TOLERANT TREAT-AND-EXTEND REGIMEN.

Grechenig C, Reiter GS, Riedl S, et al.

Retina (Philadelphia, Pa.) 2021; (41(11)):2221-2228 doi:10.1097/IAE.0000000000003180.

Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases.

Chakraborty D, Stewart MW, Sheth JU, et al.

Ophthalmology and therapy 2021; (10(2)):337-348 doi:10.1007/s40123-021-00345-2.

RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Kaiser PK, Wykoff CC, Singh RP, et al.

Retina (Philadelphia, Pa.) 2021; (41(8)):1579-1586 doi:10.1097/IAE.0000000000003194.

Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review.

Anderson WJ, da Cruz NFS, Lima LH, et al.

International journal of retina and vitreous 2021; (7(1)):37 doi:10.1186/s40942-021-00307-7.

Management of neovascular age-related macular degeneration: Taiwan expert consensus.

Yeung L, Hsieh YT, Yang CH, et al.

Journal of the Formosan Medical Association = Taiwan yi zhi 2021; (120(12)):2061-2071 doi:10.1016/j.jfma.2021.06.012.

Impact of living with a bilateral central vision loss due to geographic atrophy-qualitative study.

Madheswaran G, Ramesh SV, Pardhan S, et al.

BMJ open 2021; (11(7)):e047861 doi:10.1136/bmjopen-2020-047861.

Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration: Early Detection of Neovascular Age-Related Macular Degeneration Study.

Sivaprasad S, Banister K, Azuro-Blanco A, et al.

Ophthalmology 2021; (128(12)):1736-1747 doi:10.1016/j.ophtha.2021.07.025.

IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Literature Review.

Chaudhary V, Matonti F, Zarranz-Ventura J, Stewart MW

Retina (Philadelphia, Pa.) 2022; (42(4)):589-606 doi:10.1097/IAE.0000000000003283.

Fungal Necrotizing Scleritis After Intravitreal Injection Therapy.

Hernández-Pons A, Ortiz-Seller A, López-Cruz I, et al.

Cornea 2021; (40(12)):1617-1619 doi:10.1097/ICO.0000000000002670.

Efficacy and Safety of Anti-Vascular Endothelial Growth Factor Monotherapies for Neovascular Age-Related Macular Degeneration: A Mixed Treatment Comparison.

Zhang Y, Gao S, Li X, et al.

Frontiers in pharmacology 2021; (12()):797108 doi:10.3389/fphar.2021.797108.

Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy.

Deng Y, Qiao L, Du M, et al.

Genes & diseases 2022; (9(1)):62-79 doi:10.1016/j.gendis.2021.02.009.

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

Heier JS, Khanani AM, Quezada Ruiz C, et al.

Lancet (London, England) 2022; (399(10326)):729-740 doi:10.1016/S0140-6736(22)00010-1.

Difference Between the Incidence of Retinal Fluid Subtypes and Their Association with Visual Outcomes According to the Types of Macular Neovascularization in a Korean Population.

Kim JH, Kim JW, Kim CG

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2022; (38(3)):261-268 doi:10.1089/jop.2021.0103.

Non-invasive testing for early detection of neovascular macular degeneration in unaffected second eyes of older adults: EDNA diagnostic accuracy study.

Banister K, Cook JA, Scotland G, et al.

Health technology assessment (Winchester, England) 2022; (26(8)):1-142 doi:10.3310/VLFL1739.

Complications of intravitreal injections: 2022.

Patel D, Patel SN, Chaudhary V, Garg SJ

Current opinion in ophthalmology 2022; (33(3)):137-146 doi:10.1097/ICU.0000000000000850.

Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review.

Singh R, Davoudi S, Ness S

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2022; (260(8)):2399-2416 doi:10.1007/s00417-022-05607-8.

Novel approach to antiangiogenic factors in age-related macular degeneration therapy.

Samelska K, Kupis M, Izdebska J, et al.

Central-European journal of immunology 2022; (47(1)):117-123 doi:10.5114/ceji.2022.113103.

Long-Term Visual Outcomes in Exudative Age-Related Macular Degeneration Patients With Unanticipated Gaps in Therapy.

Bui YT, Starr MR, Kung FF, et al.

Ophthalmic surgery, lasers & imaging retina 2022; (53(9)):481-489 doi:10.3928/23258160-20220819-02.

Practical guidance for imaging biomarkers in exudative age-related macular degeneration.

Rispoli M, Cennamo G, Antonio LD, et al.

Survey of ophthalmology 2023; (68(4)):615-627 doi:10.1016/j.survophthal.2023.02.004.

Chinese Guideline on the Management of Polypoidal Choroidal Vasculopathy (2022).

Chen YX, Zhang YQ, Chen CZ, et al.

Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 2023; (38(2)):77-93 doi:10.24920/004213.

Influence of lesion location on lesion reactivation after initial treatment in neovascular age-related macular degeneration.

Kim JH, Kim JW, Kim CG

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2023; (261(11)):3139-3148 doi:10.1007/s00417-023-06144-8.

Clinical Features Associated with Acute Elevated Intraocular Pressure After Intravitreal Anti-VEGF Injections.

LoBue SA, Gindina S, Saba NJ, et al.

Clinical ophthalmology (Auckland, N.Z.) 2023; (17()):1683-1690 doi:10.2147/OPTH.S414212.

Barriers to care in neovascular age-related macular degeneration: Current understanding, developments, and future directions.

Choi A, Nawash BS, Du K, et al.

Survey of ophthalmology 2024; (69(1)):160-164 doi:10.1016/j.survophthal.2023.09.001.

Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management.

Cheung CMG

Eye (London, England) 2024; (38(4)):659-667 doi:10.1038/s41433-023-02764-w.

Mechanistic Insight into Age-Related Macular Degeneration (AMD): Anatomy, Epidemiology, Genetics, Pathogenesis, Prevention, Implications, and Treatment Strategies to Pace AMD Management.

Amini MA, Karbasi A, Vahabirad M, et al.

Chonnam medical journal 2023; (59(3)):143-159 doi:10.4068/cmj.2023.59.3.143.

Pain control and subconjunctival haemorrhage after intravitreal injection using cooled anaesthetic eyedrops and antiseptics: A prospective, double-blind, randomized controlled trial.

Moshkovsky R, Golan N, Aviel Gadot E, et al.

Acta ophthalmologica 2024; (102(4)):e587-e594 doi:10.1111/aos.15798.

Improved Structure and Function in Early-Detected Second-Eye Neovascular Age-Related Macular Degeneration: FASBAT/Early Detection of Neovascular Age-Related Macular Degeneration Report 1.

Gale RP, Airody A, Sivaprasad S, et al.

Ophthalmology. Retina 2024; (8(6)):545-552 doi:10.1016/j.oret.2023.12.012.

Age-Related Macular Degeneration: A Review.

Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U

JAMA 2024; (331(2)):147-157 doi:10.1001/jama.2023.26074.

[Quality of life survey of 3,738 patients treated with intravitreal injections for age-related macular degeneration].

Uzzan J, Haddad M, Salamé N

Journal francais d'ophtalmologie 2024; (47(3)):104075 doi:10.1016/j.jfo.2024.104075.

TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.

Khanani AM, Kotecha A, Chang A, et al.

Ophthalmology 2024; (131(8)):914-926 doi:10.1016/j.ophtha.2024.02.014.

RAHNELLA AQUATILIS ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION IN AN IMMUNOCOMPETENT PATIENT.

Williams PJ, Xue G, Ross BX, et al.

Retinal cases & brief reports 2025; (19(3)):311-314 doi:10.1097/ICB.0000000000001567.

Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.

Lanzetta P, Korobelnik JF, Heier JS, et al.

Lancet (London, England) 2024; (403(10432)):1141-1152 doi:10.1016/S0140-6736(24)00063-1.

Home-monitoring for neovascular age-related macular degeneration in older adults within the UK: the MONARCH diagnostic accuracy study.

Hogg RE, Wickens R, O'Connor S, et al.

Health technology assessment (Winchester, England) 2024; (28(32)):1-136 doi:10.3310/CYRA9912.

Recent Updates on the Diagnosis and Management of Age-Related Macular Degeneration.

Boopathiraj N, Wagner IV, Dorairaj SK, et al.

Mayo Clinic proceedings. Innovations, quality & outcomes 2024; (8(4)):364-374 doi:10.1016/j.mayocpiqo.2024.05.003.

Macular neovascularization.

Sheth JU, Stewart MW, Narayanan R, et al.

Survey of ophthalmology 2025; (70(4)):653-675 doi:10.1016/j.survophthal.2024.08.003.

Reactivation of stable neovascular age-related macular degeneration following treat-and-extend regimen discontinuation.

Artiaga JCM, Wong SW, Menon D, et al.

Clinical & experimental ophthalmology 2025; (53(1)):76-83 doi:10.1111/ceo.14444.

Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration.

Loewenstein A, Sylvanowicz M, Amoaku WM, et al.

Ophthalmology and therapy 2025; (14(1)):211-228 doi:10.1007/s40123-024-01061-3.

The Past, Present, and Future Perspective of Photodynamic Therapy for Age-Related Macular Degeneration.

Honda S

Journal of clinical medicine 2025; (14(4)) doi:10.3390/jcm14041240.

Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis.

Butler ETS, Arnold-Vangsted A, Schou MG, et al.

Acta ophthalmologica 2025; (103(7)):741-763 doi:10.1111/aos.17506.

Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study.

Falemban AH, Söderberg-Löfdal K, Jonsson F, et al.

Acta ophthalmologica 2025; doi:10.1111/aos.17534.

Intraocular inflammation following intravitreal injections of anti-vascular endothelial growth factor drugs.

Ferreira AM, Mendes AF, Beato JN, et al.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2025; (263(10)):2885-2892 doi:10.1007/s00417-025-06875-w.

Japanese clinical guidelines for neovascular age-related macular degeneration.

Iida T, Gomi F, Yasukawa T, et al.

Japanese journal of ophthalmology 2025; (69(4)):639-660 doi:10.1007/s10384-025-01240-0.

Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.

Korobelnik JF, Lanzetta P, Leal S, et al.

Ophthalmology 2026; (133(1)):39-50 doi:10.1016/j.ophtha.2025.08.022.

Transient vision and intraocular pressure changes following anti-vascular endothelial growth factor injection.

Abbas K, Basilious A, Duncan J, et al.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2026; (61(2)):412-421 doi:10.1016/j.jcjo.2025.09.005.

Intraocular Inflammation After Intravitreal Faricimab Injections: A Case Series.

Loo Y, Lim J, Chew MCY, et al.

Clinical & experimental ophthalmology 2026; (54(4)):507-513 doi:10.1111/ceo.70058.

SD-OCT AND OCTA: Distinct or Additional Information on Neovascular Activity? The COCTAEYL Study.

Amoroso F, Miere A, Kodjikian L, et al.

Retina (Philadelphia, Pa.) 2026; (46(7)):1203-1211 doi:10.1097/IAE.0000000000004815.

Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.

Koksaldi S, Kayabasi M, Karti O, Saatci AO

Medical hypothesis, discovery & innovation ophthalmology journal 2026; (15(1)):40-68 doi:10.51329/mehdiophthal1539.

Real World Data About the Treatment of Wet Age-Related Macular Degeneration in Kuopio University Hospital During 2019-2021 Using a PRN Regimen.

Hiltunen TO, Kaarniranta K, Kivinen N

Clinical ophthalmology (Auckland, N.Z.) 2026; (20()):595553 doi:10.2147/OPTH.S595553.

Murine models of neovascular AMD revisited: Mechanistic pathways, immune-metabolic crosstalk, and the impact of aging and sex.

Harris C, Nisar MA, Amamoo R, et al.

Experimental eye research 2026; (270()):111094 doi:10.1016/j.exer.2026.111094.

Quality of life in patients with neovascular age-related macular degeneration before and after intravitreal therapy: a longitudinal observational study.

Nowak M, Cybulska AM, Derezińska A, et al.

Frontiers in medicine 2026; (13()):1731481 doi:10.3389/fmed.2026.1731481.

Non-exudative fluid in age-related macular degeneration: Imaging, pathophysiology, and clinical implications.

Vienne-Jumeau A, Merle D, Sacconi R, Querques G

Survey of ophthalmology 2026; doi:10.1016/j.survophthal.2026.07.008.

Variations in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy Phenotypes and Treatment Outcomes Across Singaporean, Canadian Asian, and Canadian Caucasian Populations.

Huang A, Ling J, Gilead N, et al.

American journal of ophthalmology 2026; (292()):163-174 doi:10.1016/j.ajo.2026.08.018.